duloxetine

Therapeutic Classification: antidepressants

Pharmacologic Classification: selective serotonin and norepinephrine reuptake inhibitors-SSNRIs

BEERS REMS

Major depressive disorder.
Diabetic peripheral neuropathic pain.
Generalized anxiety disorder.
Chronic musculoskeletal pain (including chronic lower back pain and chronic pain from osteoarthritis).
Fibromyalgia.

Inhibits serotonin and norepinephrine reuptake in the CNS. Both antidepressant and pain inhibition are centrally mediated.

Therapeutic effects:

Decreased depressive symptomatology.
Decreased neuropathic pain.
Decreased symptoms of anxiety.
Decreased pain.

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Protein Binding: >90%.

Metabolism/Excretion: Primarily metabolized in the liver via the CYP2D6 and CYP1A2 isoenzymes; the CYP2D6 isoenzyme exhibits genetic polymorphism; ∼7% of population may be poor metabolizers and may have significantly ↑ duloxetine concentrations and an ↑ risk of adverse effects.

Half-Life: 12 hr.

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
PO	unknown	6 hr	12 hr

Contraindicated in:

Hypersensitivity;
Concurrent use of MAO inhibitors or MAO-like drugs (linezolid or methylene blue);
Severe renal impairment;
Hepatic impairment or substantial alcohol use (↑ risk of hepatitis).

Use Cautiously in:

May ↑ risk of suicide attempt/ideation, especially during early treatment or dose adjustment; this risk appears to be greater in adolescents or children;
History of mania (may activate mania/hypomania);
History of seizure disorder;
Diabetes (may worsen glycemic control);
Angle-closure glaucoma;
OB: Use during 3rd trimester may result in neonatal serotonin syndrome, requiring prolonged hospitalization and respiratory and nutritional support; may ↑ risk of postpartum hemorrhage in mother when used in the month before delivery;
Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant;
Pedi: Safety and effectiveness not established in children <7 yr (generalized anxiety disorder) or <13 yr (fibromyalgia);
Geri: Appears on Beers list. May worsen or cause syndrome of inappropriate antidiuretic hormone (SIADH) secretion and/or hyponatremia in older adults. Use with caution in older adults and closely monitor sodium concentrations when starting therapy or ↑ dose.

CV: hypertension, orthostatic hypotension

Derm: ↑sweating, ERYTHEMA MULTIFORME, pruritus, rash, STEVENS-JOHNSON SYNDROME (SJS)

EENT: ↑intraocular pressure, blurred vision

Endo: SIADH

F and E: hyponatremia

GI: constipation, dry mouth, nausea, ↑liver enzymes, diarrhea, gastritis, HEPATOTOXICITY, PANCREATITIS, vomiting

GU: dysuria, ↓libido, delayed/absent orgasm, ejaculatory delay/failure, erectile dysfunction, urinary retention

Hemat: BLEEDING

Metab: ↓appetite

Neuro: drowsiness, fatigue, insomnia, activation of mania, dizziness, fainting, falls, NEUROLEPTIC MALIGNANT SYNDROME, nightmares, SEIZURES, SUICIDAL THOUGHTS/BEHAVIORS, tremor

Misc: SEROTONIN SYNDROME

Drug-drug:

Concurrent use with MAO inhibitors may result in serious potentially fatal reactions; do not use within 14 days of discontinuing MAO inhibitor; wait at least 5 days after stopping duloxetine to start MAO inhibitor.
Concurrent use with MAO-inhibitor-like drugs, such as linezolid or methylene blue, may ↑ risk of serotonin syndrome; concurrent use contraindicated; do not start therapy in patients receiving linezolid or methylene blue; if linezolid or methylene blue need to be started in a patient receiving duloxetine, immediately discontinue duloxetine and monitor for signs/symptoms of serotonin syndrome for 5 days or until 24 hr after last dose of linezolid or methylene blue, whichever comes first (may resume duloxetine therapy 24 hr after last dose of linezolid or methylene blue).
↑risk of hepatotoxicity with alcohol use disorder/alcohol abuse.
Drugs that affect serotonergic neurotransmitter systems, including tricyclic antidepressants, SNRIs, fentanyl, lithium, buspirone, tramadol, meperidine, methadone, amphetamines, and triptans, may ↑ risk of serotonin syndrome.
Strong CYP1A2 inhibitors, including cimetidine, ciprofloxacin, and fluvoxamine, may ↑ levels and risk of toxicity; avoid concurrent use.
CYP2D6 inhibitors, including paroxetine, fluoxetine, and quinidine, may ↑ levels and risk of toxicity.
May ↑ levels and risk of toxicity of CYP2D6 substrates, including TCAs, phenothiazines, and class Ic antiarrhythmics (propafenone and flecainide); concurrent use should be undertaken with caution.
↑risk of serious arrhythmias with thioridazine; avoid concurrent use.
↑risk of bleeding with NSAIDs, aspirin, clopidogrel, prasugrel, ticagrelor, dabigatran, apixaban, edoxaban, rivaroxaban, or warfarin.

Drug-Natural Products:

St. John's wort may ↑ risk of serotonin syndrome.

Major Depressive Disorder

PO (Adults ): 40–60 mg/day (as 20 mg or 30 mg twice daily or as 60 mg once daily) as initial therapy; then 60 mg once daily as maintenance therapy.

Generalized Anxiety Disorder

PO (Adults ≥65 yr): 30 mg once daily for 2 wk; may then consider ↑ to 60 mg once daily; then may ↑ by 30 mg once daily to maintenance dose of 60–120 mg once daily.
PO (Adults <65 yr): 30–60 mg once daily as initial therapy (if initiated on 30 mg once daily, should titrate to 60 mg once daily after 1 wk); may then ↑ by 30 mg once daily to maintenance dose of 60–120 mg once daily.
PO (Children ≥7 yr): 30 mg once daily for 2 wk; may then consider ↑ to 60 mg once daily; recommended maintenance dose = 30–60 mg once daily (not to exceed 120 mg once daily).

Diabetic Peripheral Neuropathic Pain

PO (Adults ): 60 mg once daily.

Fibromyalgia

PO (Adults ): 30 mg once daily for 1 wk; then ↑ to 60 mg once daily.
PO (Children ≥13 yr): Cymbalta only: 30 mg once daily; may ↑ to 60 mg once daily based on response and tolerability.

Chronic Musculoskeletal Pain

PO (Adults ): 30 mg once daily for 1 wk; then ↑ to 60 mg once daily.

(Generic available)

Delayed-release capsules: 20 mg; 30 mg; 40 mg; 60 mg

Monitor BP before and periodically during therapy. Sustained hypertension may be dose related; ↓ dose or discontinue therapy if this occurs.
Monitor appetite and nutritional intake. Weigh weekly. Report continued weight loss. Adjust diet as tolerated to support nutritional status.
Assess sexual function before starting duloxetine. Assess for changes in sexual function during treatment, including timing of onset; patient may not report.
Assess mental status and mood changes. Inform health care provider if patient demonstrates significant ↑ in anxiety, nervousness, or insomnia.
Assess for suicidal tendencies, especially during early therapy. Restrict amount of drug available to patient. Risk may be ↑ in children, adolescents, and adults ≤24 yr. After starting therapy, children, adolescents, and young adults should be seen by health care provider at least weekly for 4 wk, every 3 wk for next 4 wk, and on advice of health care provider thereafter.
Assess for serotonin syndrome (mental changes [agitation, hallucinations, coma], autonomic instability [tachycardia, labile BP, hyperthermia], neuromuscular aberrations [hyperreflexia, incoordination], or GI symptoms [nausea, vomiting, diarrhea]), especially in patients taking other serotonergic drugs (SSRIs, SNRIs, triptans).
Assess for rash periodically during therapy. May cause SJS. Discontinue therapy if severe or if accompanied with fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis, or eosinophilia.
Depression or Anxiety: Assess mental status (orientation, mood, behavior). Inform health care provider if patient demonstrates significant ↑ in anxiety, nervousness, or insomnia.
Pain or Fibromyalgia: Assess intensity, quality, and location of pain periodically during therapy. May require several wk for effects to be seen.

Lab Test Considerations:

May cause ↑ ALT, AST, bilirubin, CK, and alkaline phosphatase.
- May cause hyponatremia.
- Monitor blood sugar and A1c. May cause slight ↑ in blood glucose.

Do not confuse duloxetine with fluoxetine, paroxetine, or Dexilant. Do not confuse Cymbalta with Symbyax.
PO: May be administered without regard to meals. DNC: Swallow capsules whole; do not crush, chew, or open and sprinkle contents on food or liquids.

Explain purpose and side effects of medication to patient. Advise patient to read Patient Information before starting therapy. Instruct patient to take as directed at the same time each day. Take missed doses as soon as possible unless time for next dose. Do not stop abruptly; may cause dizziness, headache, nausea, diarrhea, paresthesia, irritability, vomiting, insomnia, anxiety, hyperhidrosis, and fatigue; must be ↓ gradually. Advise patients they may notice improvement within 1–4 wk, but should be advised to continue therapy as directed. Therapy is usually continued for several months.
Instruct patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care provider before taking other medications, especially NSAIDs or aspirin.
Advise patient, family, and caregivers to look for suicidality, especially during early therapy or dose changes. Notify health care provider immediately if thoughts about suicide or dying, attempts to commit suicide, new or worse depression or anxiety, agitation or restlessness, panic attacks, insomnia, new or worse irritability, aggressiveness, acting on dangerous impulses, mania, or other changes in mood or behavior occur.
May cause drowsiness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
Geri: Advise patient to make position changes slowly to minimize orthostatic hypotension and falls, especially in older adults and those taking antihypertensive medications.
Instruct patient to notify health care provider if signs of serotonin syndrome (mental status changes: agitation, hallucinations, coma), autonomic instability (tachycardia, labile BP, hyperthermia), neuromuscular aberrations (hyperreflexia, incoordination), gastrointestinal symptoms (nausea, vomiting, diarrhea), liver damage (pruritus, dark urine, jaundice, right upper quadrant tenderness, unexplained flu-like symptoms), bleeding (ecchymoses, hematomas, epistaxis, petechiae, hemorrhage), or rash occur.
Advise patient to avoid taking alcohol during therapy.
Inform patient that duloxetine may cause symptoms of sexual dysfunction. In men, ejaculatory delay or failure, ↓ libido, and erectile dysfunction may occur. In women, may result in ↓ libido and delayed or absent orgasm. Advise patient to notify health care provider if symptoms occur.
Rep: May cause fetal harm. Advise women of reproductive potential to notify health care provider if pregnancy is planned or suspected or if breastfeeding. Use late in 3rd trimester may result in neonatal serotonin syndrome requiring prolonged hospitalization, respiratory support, and tube feeding; may occur immediately upon delivery. Symptoms include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. Use of duloxetine in last month of pregnancy may ↑ risk of postpartum hemorrhage. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Encourage health care providers to register patients by contacting the National Pregnancy Registry for Antidepressants at 1-866-961-2388 or online at https://womensmentalhealth.org/research/pregnancyregistry/. Monitor infants exposed to duloxetine via breastfeeding for sedation, poor feeding, and poor weight gain.

Decreased depressive symptomatology.
Decreased neuropathic pain.
Decrease pain.
Decrease anxiety.

NDC Code

0002- Eli Lilly and Company
- 0002-3235- Cymbalta
  - 0002-3235-60- 60 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0002-3235-60)

0002- Eli Lilly and Company
- 0002-3240- Cymbalta
  - 0002-3240-30- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0002-3240-30)

0002- Eli Lilly and Company
- 0002-3240- Cymbalta
  - 0002-3240-90- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0002-3240-90)

0002- Eli Lilly and Company
- 0002-3270- Cymbalta
  - 0002-3270-30- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0002-3270-30)

0110- Lilly del Caribe, Inc.
- 0110-3235-
  - 0110-3235-05- 300000 CAPSULE, DELAYED RELEASE in 1 DRUM (0110-3235-05)

0110- Lilly del Caribe, Inc.
- 0110-3240-
  - 0110-3240-05- 250000 CAPSULE, DELAYED RELEASE in 1 DRUM (0110-3240-05)

0110- Lilly del Caribe, Inc.
- 0110-3270-
  - 0110-3270-05- 150000 CAPSULE, DELAYED RELEASE in 1 DRUM (0110-3270-05)

0110- Lilly del Caribe, Inc.
- 0110-9542-
  0110-9542-15- 155000 CAPSULE, DELAYED RELEASE in 1 DRUM (0110-9542-15)

0110- Lilly del Caribe, Inc.
- 0110-9543-
  0110-9543-15- 250000 CAPSULE, DELAYED RELEASE in 1 DRUM (0110-9543-15)

0110- Lilly del Caribe, Inc.
- 0110-9544-
  0110-9544-15- 300000 CAPSULE, DELAYED RELEASE in 1 DRUM (0110-9544-15)

0110- Lilly del Caribe, Inc.
- 0110-9545-
  0110-9545-15- 200000 CAPSULE, DELAYED RELEASE in 1 DRUM (0110-9545-15)

0228- Actavis Pharma, Inc.
- 0228-2890-
  0228-2890-00- 26792 CAPSULE, DELAYED RELEASE PELLETS in 1 CONTAINER (0228-2890-00)

0228- Actavis Pharma, Inc.
- 0228-2890- Duloxetine
  0228-2890-06- 60 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (0228-2890-06)

0228- Actavis Pharma, Inc.
- 0228-2891-
  - 0228-2891-00- 18613 CAPSULE, DELAYED RELEASE PELLETS in 1 CONTAINER (0228-2891-00)

0228- Actavis Pharma, Inc.
- 0228-2891- Duloxetine
  0228-2891-03- 30 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (0228-2891-03)

0228- Actavis Pharma, Inc.
- 0228-2891- Duloxetine
  - 0228-2891-50- 500 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (0228-2891-50)

0228- Actavis Pharma, Inc.
- 0228-2892-
  - 0228-2892-00- 10209 CAPSULE, DELAYED RELEASE PELLETS in 1 CONTAINER (0228-2892-00)

0228- Actavis Pharma, Inc.
- 0228-2892- Duloxetine
  0228-2892-03- 30 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (0228-2892-03)

0228- Actavis Pharma, Inc.
- 0228-2892- Duloxetine
  - 0228-2892-96- 1000 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (0228-2892-96)

0615- NCS HealthCare of KY, LLC dba Vangard Labs
- 0615-8494- Duloxetine
  - 0615-8494-39- 30 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK (0615-8494-39)

0615- NCS HealthCare of KY, LLC dba Vangard Labs
- 0615-8495- Duloxetine
  - 0615-8495-05- 15 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK (0615-8495-05)

0615- NCS HealthCare of KY, LLC dba Vangard Labs
- 0615-8495- Duloxetine
  - 0615-8495-39- 30 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK (0615-8495-39)

0615- NCS HealthCare of KY, LLC dba Vangard Labs
- 0615-8496- Duloxetine
  - 0615-8496-05- 15 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK (0615-8496-05)

0615- NCS HealthCare of KY, LLC dba Vangard Labs
- 0615-8496- Duloxetine
  - 0615-8496-28- 28 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK (0615-8496-28)

0615- NCS HealthCare of KY, LLC dba Vangard Labs
- 0615-8496- Duloxetine
  - 0615-8496-39- 30 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK (0615-8496-39)

0904- Major Pharmaceuticals
- 0904-7043- Duloxetine
  - 0904-7043-04- 30 BLISTER PACK in 1 CARTON (0904-7043-04) / 1 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK

0904- Major Pharmaceuticals
- 0904-7043- Duloxetine
  - 0904-7043-61- 100 BLISTER PACK in 1 CARTON (0904-7043-61) / 1 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK

0904- Major Pharmaceuticals
- 0904-7044- Duloxetine
  - 0904-7044-61- 100 BLISTER PACK in 1 CARTON (0904-7044-61) / 1 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK

0904- Major Pharmaceuticals
- 0904-7045- Duloxetine
  - 0904-7045-61- 100 BLISTER PACK in 1 CARTON (0904-7045-61) / 1 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK

14501- MSN Laboratories Private Limited
- 14501-0005-
  - 14501-0005-2- 50 kg in 1 DRUM (14501-0005-2)

17337- Olon SpA
- 17337-0017-
  17337-0017-1- 20 kg in 1 DRUM (17337-0017-1)

17337- Olon SpA
- 17337-0046-
  17337-0046-1- 20 kg in 1 DRUM (17337-0046-1)

25000- MARKSANS PHARMA LIMITED
- 25000-608- Duloxetine
  25000-608-06- 60 CAPSULE, DELAYED RELEASE in 1 BOTTLE (25000-608-06)

25000- MARKSANS PHARMA LIMITED
- 25000-609- Duloxetine
  - 25000-609-03- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (25000-609-03)

25000- MARKSANS PHARMA LIMITED
- 25000-609- Duloxetine
  - 25000-609-07- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (25000-609-07)

25000- MARKSANS PHARMA LIMITED
- 25000-610- Duloxetine
  - 25000-610-03- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (25000-610-03)

25000- MARKSANS PHARMA LIMITED
- 25000-610- Duloxetine
  - 25000-610-07- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (25000-610-07)

27241- Ajanta Pharma USA Inc.
- 27241-097- Duloxetine
  - 27241-097-05- 500 CAPSULE, DELAYED RELEASE in 1 BOTTLE (27241-097-05)

27241- Ajanta Pharma USA Inc.
- 27241-097- Duloxetine
  - 27241-097-06- 60 CAPSULE, DELAYED RELEASE in 1 BOTTLE (27241-097-06)

27241- Ajanta Pharma USA Inc.
- 27241-097- Duloxetine
  - 27241-097-10- 1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (27241-097-10)

27241- Ajanta Pharma USA Inc.
- 27241-097- Duloxetine
  - 27241-097-90- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (27241-097-90)

27241- Ajanta Pharma USA Inc.
- 27241-098- Duloxetine
  - 27241-098-03- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (27241-098-03)

27241- Ajanta Pharma USA Inc.
- 27241-098- Duloxetine
  - 27241-098-09- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (27241-098-09)

27241- Ajanta Pharma USA Inc.
- 27241-098- Duloxetine
  - 27241-098-10- 1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (27241-098-10)

27241- Ajanta Pharma USA Inc.
- 27241-099- Duloxetine
  - 27241-099-03- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (27241-099-03)

27241- Ajanta Pharma USA Inc.
- 27241-099- Duloxetine
  - 27241-099-40- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (27241-099-40)

27241- Ajanta Pharma USA Inc.
- 27241-099- Duloxetine
  - 27241-099-90- 1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (27241-099-90)

27241- Ajanta Pharma USA Inc.
- 27241-164- Duloxetine
  - 27241-164-30- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (27241-164-30)

31722- Camber Pharmaceuticals, Inc.
- 31722-168- Duloxetine
  - 31722-168-01- 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE (31722-168-01)

31722- Camber Pharmaceuticals, Inc.
- 31722-168- Duloxetine
  - 31722-168-05- 500 CAPSULE, DELAYED RELEASE in 1 BOTTLE (31722-168-05)

31722- Camber Pharmaceuticals, Inc.
- 31722-168- Duloxetine
  - 31722-168-10- 1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (31722-168-10)

31722- Camber Pharmaceuticals, Inc.
- 31722-168- Duloxetine
  - 31722-168-30- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (31722-168-30)

31722- Camber Pharmaceuticals, Inc.
- 31722-168- Duloxetine
  - 31722-168-31- 7 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK (31722-168-31)

31722- Camber Pharmaceuticals, Inc.
- 31722-168- Duloxetine
  - 31722-168-32- 105 CAPSULE, DELAYED RELEASE in 1 CARTON (31722-168-32)

31722- Camber Pharmaceuticals, Inc.
- 31722-168- Duloxetine
  - 31722-168-60- 60 CAPSULE, DELAYED RELEASE in 1 BOTTLE (31722-168-60)

31722- Camber Pharmaceuticals, Inc.
- 31722-168- Duloxetine
  - 31722-168-90- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (31722-168-90)

31722- Camber Pharmaceuticals, Inc.
- 31722-169- Duloxetine
  - 31722-169-01- 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE (31722-169-01)

31722- Camber Pharmaceuticals, Inc.
- 31722-169- Duloxetine
  - 31722-169-10- 1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (31722-169-10)

31722- Camber Pharmaceuticals, Inc.
- 31722-169- Duloxetine
  - 31722-169-30- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (31722-169-30)

31722- Camber Pharmaceuticals, Inc.
- 31722-169- Duloxetine
  - 31722-169-31- 7 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK (31722-169-31)

31722- Camber Pharmaceuticals, Inc.
- 31722-169- Duloxetine
  - 31722-169-32- 105 CAPSULE, DELAYED RELEASE in 1 CARTON (31722-169-32)

31722- Camber Pharmaceuticals, Inc.
- 31722-169- Duloxetine
  - 31722-169-90- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (31722-169-90)

31722- Camber Pharmaceuticals, Inc.
- 31722-170- Duloxetine
  - 31722-170-01- 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE (31722-170-01)

31722- Camber Pharmaceuticals, Inc.
- 31722-170- Duloxetine
  - 31722-170-10- 1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (31722-170-10)

31722- Camber Pharmaceuticals, Inc.
- 31722-170- Duloxetine
  - 31722-170-30- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (31722-170-30)

31722- Camber Pharmaceuticals, Inc.
- 31722-170- Duloxetine
  - 31722-170-31- 7 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK (31722-170-31)

31722- Camber Pharmaceuticals, Inc.
- 31722-170- Duloxetine
  - 31722-170-90- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (31722-170-90)

33342- Macleods Pharmaceuticals Limited
- 33342-160- Duloxetine Hydrochloride
  - 33342-160-09- 60 CAPSULE, DELAYED RELEASE in 1 BOTTLE (33342-160-09)

33342- Macleods Pharmaceuticals Limited
- 33342-160- Duloxetine Hydrochloride
  - 33342-160-10- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (33342-160-10)

33342- Macleods Pharmaceuticals Limited
- 33342-160- Duloxetine Hydrochloride
  - 33342-160-12- 10 BLISTER PACK in 1 CARTON (33342-160-12) / 10 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK

33342- Macleods Pharmaceuticals Limited
- 33342-160- Duloxetine Hydrochloride
  - 33342-160-44- 1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (33342-160-44)

33342- Macleods Pharmaceuticals Limited
- 33342-161- Duloxetine Hydrochloride
  - 33342-161-07- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (33342-161-07)

33342- Macleods Pharmaceuticals Limited
- 33342-161- Duloxetine Hydrochloride
  - 33342-161-10- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (33342-161-10)

33342- Macleods Pharmaceuticals Limited
- 33342-161- Duloxetine Hydrochloride
  - 33342-161-12- 10 BLISTER PACK in 1 CARTON (33342-161-12) / 10 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK

33342- Macleods Pharmaceuticals Limited
- 33342-161- Duloxetine Hydrochloride
  - 33342-161-44- 1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (33342-161-44)

33342- Macleods Pharmaceuticals Limited
- 33342-162- Duloxetine Hydrochloride
  - 33342-162-07- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (33342-162-07)

33342- Macleods Pharmaceuticals Limited
- 33342-162- Duloxetine Hydrochloride
  - 33342-162-10- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (33342-162-10)

33342- Macleods Pharmaceuticals Limited
- 33342-162- Duloxetine Hydrochloride
  - 33342-162-12- 10 BLISTER PACK in 1 CARTON (33342-162-12) / 10 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK

33342- Macleods Pharmaceuticals Limited
- 33342-162- Duloxetine Hydrochloride
  - 33342-162-44- 1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (33342-162-44)

43063- PD-Rx Pharmaceuticals, Inc.
- 43063-877- Duloxetine
  - 43063-877-90- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE, PLASTIC (43063-877-90)

43063- PD-Rx Pharmaceuticals, Inc.
- 43063-878- Duloxetine
  - 43063-878-30- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE, PLASTIC (43063-878-30)

43063- PD-Rx Pharmaceuticals, Inc.
- 43063-878- Duloxetine
  - 43063-878-90- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE, PLASTIC (43063-878-90)

43353- Aphena Pharma Solutions - Tennessee, LLC
- 43353-025- Duloxetine Delayed-Release
  - 43353-025-30- 30 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (43353-025-30)

43353- Aphena Pharma Solutions - Tennessee, LLC
- 43353-025- Duloxetine Delayed-Release
  - 43353-025-60- 90 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (43353-025-60)

43353- Aphena Pharma Solutions - Tennessee, LLC
- 43353-106- Duloxetine Delayed-Release
  - 43353-106-16- 6000 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (43353-106-16)

43353- Aphena Pharma Solutions - Tennessee, LLC
- 43353-106- Duloxetine Delayed-Release
  - 43353-106-33- 840 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (43353-106-33)

43353- Aphena Pharma Solutions - Tennessee, LLC
- 43353-106- Duloxetine Delayed-Release
  - 43353-106-74- 500 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (43353-106-74)

43353- Aphena Pharma Solutions - Tennessee, LLC
- 43353-106- Duloxetine Delayed-Release
  - 43353-106-83- 3600 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (43353-106-83)

43353- Aphena Pharma Solutions - Tennessee, LLC
- 43353-960- Duloxetine Delayed-Release
  - 43353-960-30- 30 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (43353-960-30)

43353- Aphena Pharma Solutions - Tennessee, LLC
- 43353-960- Duloxetine Delayed-Release
  - 43353-960-42- 1800 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (43353-960-42)

43353- Aphena Pharma Solutions - Tennessee, LLC
- 43353-960- Duloxetine Delayed-Release
  - 43353-960-83- 3600 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (43353-960-83)

43547- Solco Healthcare US, LLC
- 43547-379- DULOXETINE
  - 43547-379-03- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (43547-379-03)

43547- Solco Healthcare US, LLC
- 43547-379- DULOXETINE
  - 43547-379-06- 60 CAPSULE, DELAYED RELEASE in 1 BOTTLE (43547-379-06)

43547- Solco Healthcare US, LLC
- 43547-379- DULOXETINE
  - 43547-379-09- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (43547-379-09)

43547- Solco Healthcare US, LLC
- 43547-379- DULOXETINE
  - 43547-379-11- 1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (43547-379-11)

43547- Solco Healthcare US, LLC
- 43547-380- DULOXETINE
  - 43547-380-03- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (43547-380-03)

43547- Solco Healthcare US, LLC
- 43547-380- DULOXETINE
  - 43547-380-09- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (43547-380-09)

43547- Solco Healthcare US, LLC
- 43547-380- DULOXETINE
  - 43547-380-11- 1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (43547-380-11)

43547- Solco Healthcare US, LLC
- 43547-381- DULOXETINE
  - 43547-381-03- 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (43547-381-03)

43547- Solco Healthcare US, LLC
- 43547-381- DULOXETINE
  - 43547-381-09- 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (43547-381-09)

43547- Solco Healthcare US, LLC
- 43547-381- DULOXETINE
  - 43547-381-11- 1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (43547-381-11)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Pill Image

Code ⬆